Oct 8, 2025
KITS Eyecare (KITS) fell 8% on its preliminary Q3 results, which were strong at 25% Y/Y revenue growth…
… and 5% adj. EBITDA margins, as the operating leverage inherent in KITS’ business model starts to show with scale.
With the stock doubling this year, investors were likely looking for a big beat - feels like a breather rather than a change in the thesis.
Disclaimer: Content on this site, including research reports, is provided by Bullpen Finance Inc. for informational purposes only and does not constitute investment advice. Bullpen Finance Inc. receives compensation from issuers for research coverage; such compensation does not influence opinions expressed. For complete disclosures, please see our Legal & Disclosures section.
